The usual vitamin D blood test measures 25-hydroxyvitamin D, written as 25(OH)D.[1] Its interpretation depends on units, the laboratory method and the reason for testing.[1][2][3] Population reference levels and recommendations about routine screening answer different questions.[1][2][3]
The marker on the report
25(OH)D reflects vitamin D from skin exposure, food and supplements.[1] The liver makes this form before further conversion to the active form, chiefly in the kidneys.[1]
The active form, 1,25-dihydroxyvitamin D, usually gives a poor measure of vitamin D status.[1] Its blood concentration is tightly regulated and can remain normal until deficiency becomes severe.[1] The names of these two tests therefore matter when comparing results.[1]
Some reports use ng/mL, while others use nmol/L.[1] One ng/mL equals 2.5 nmol/L.[1] For example, 20 ng/mL and 50 nmol/L describe the same concentration.[1] Laboratory methods can also produce different results from the same sample.[1]
What US reference levels describe
The National Academies' framework concerns vitamin D status and adequacy for most healthy people.[1] NIH summarizes it as follows.[1]
| 25(OH)D concentration | Interpretation in that framework |
|---|---|
| Below 12 ng/mL (30 nmol/L)[1] | Associated with risk of deficiency.[1] |
| 12 to below 20 ng/mL (30 to below 50 nmol/L)[1] | Generally considered inadequate.[1] |
| At least 20 ng/mL (50 nmol/L)[1] | Generally adequate for most healthy people.[1] |
| Above 50 ng/mL (125 nmol/L)[1] | Associated with possible adverse effects, especially above 60 ng/mL (150 nmol/L).[1] |
Source: NIH ODS, Table 1, summarizing the National Academies. These categories describe population reference levels.[1]
A laboratory result needs its clinical context, including the reason the test was ordered.[1][3]
Why recommendations about testing differ
In 2021, the US Preventive Services Task Force found insufficient evidence to determine whether the benefits of routine screening outweigh the harms.[2] Its statement covered nonpregnant adults living in the community who had no signs or symptoms of vitamin D deficiency.[2] It excluded people with conditions for which medical use of vitamin D was already indicated.[2]
The Endocrine Society's 2024 guideline suggests against routine testing in generally healthy adults without established indications.[3] Trials had not established blood concentrations linked to specific preventive benefits in these groups.[3] The guideline addresses routine care in otherwise healthy people.[3] An established indication, such as low blood calcium, changes its applicability.[3]
Neither statement supplies a universal target for interpreting every already-ordered test.[2][3]
The Endocrine Society’s 2011 guideline used 30 ng/mL (75 nmol/L) as the lower end of its range for sufficiency.[4] In its 2024 update on disease risk, the society dropped that general target for otherwise healthy people.[3][4] The trials it reviewed did not establish a blood level that predicts who would benefit from supplementation.[3][4] The Bone Health and Osteoporosis Foundation’s guide for postmenopausal women and men aged 50 and older identifies 30 ng/mL (75 nmol/L) as the lower end of its clinical range for known or suspected metabolic bone disease.[1][5]
Comparing results over time
The test name, units, laboratory method and interval between samples belong beside the numbers.[1] A difference between two 25(OH)D results can reflect a change in your vitamin D level, differences in how the samples were measured, or both.[1] Symptoms and clinical outcomes require their own assessment.[1][3]
How long vitamin D levels take to rise explains how quickly the blood marker changed in a trial. The vitamin D guide covers food, forms, US reference intakes and the upper limit.
Information, not a prescription. Do not start, stop or combine supplements or medicines on your own.
Sources
- NIH Office of Dietary Supplements. Vitamin D: Fact Sheet for Health Professionals. Introduction, Assessing vitamin D status and Table 1. Official synthesis; population categories do not prescribe an individual target. ↩
- US Preventive Services Task Force. Vitamin D Deficiency in Adults: Screening. April 2021. Recommendation statement; its scope is asymptomatic, nonpregnant adults living in the community. It excludes conditions for which vitamin D treatment is already indicated. A supplementation dose and study funding entry are not applicable to this recommendation. ↩
- Endocrine Society. Vitamin D for the Prevention of Disease. 2024; recommendations on routine testing and their technical remarks. Clinical guideline; established indications fall outside the routine-screening question. A single trial population, dose or follow-up period does not apply. ↩
- McCartney CR, McDonnell ME, Corrigan MD, Lash RW. Vitamin D Insufficiency and Epistemic Humility: An Endocrine Society Guideline Communication. Journal of Clinical Endocrinology & Metabolism. 2024. Published communication. PubMed abstract. Previous sufficiency threshold and the reason for withdrawing it for generally healthy people. ↩
- LeBoff MS, et al. The clinician’s guide to prevention and treatment of osteoporosis. Osteoporosis International. 2022. Full guide, synopsis of major recommendations. PMC full text. Bone Health and Osteoporosis Foundation guidance for postmenopausal women and men aged 50 and older. ↩
You may quote, republish or translate this article under CC BY 4.0: credit “Verateca”, link to this page and indicate changes, including translations. Quotes from NIH, FDA and other sources, label texts and prices are not covered by this license.